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Introduction 
Medications remain a mainstay of treating chronic disease states and recent research 
shows that there is an increasing trend in the overall use of prescription drugs among US adults. 
Approximately 51% of US adults in 1999-2000 reported prescription drug use, which increased 
to 59% in 2011-2012 (Kantor, 2015). Use of medications also represents a major expenditure in 
the US, with data showing that per capita spending on prescription drugs is $858 compared with 
an average of $400 for 19 other industrialized nations (Kesselheim, 2016). Increased medication 
use is often associated with unnecessary medication use, increased risk of adverse events, and 
non-adherence (Sabate, 2003). All medications have the potential to cause side effects and some 
carry the risk of serious adverse events. Patients need be informed and involved in the decision-
making making process for the selection of medications necessary to treat their conditions. They 
require a better understanding of the potential harms and benefits of medications to make 
informed decisions regarding therapy (Whitney, 2004).  
 Three types of written medical information (WMI) exist for patients in the US as 
important sources of information to help make these decisions. The Food and Drug 
Administration (FDA) requires Medication Guides and patient package inserts to accompany 
some medications. The other form of WMI is consumer medication information (CMI), which 
often times describe adverse events of medications in terms of qualitative descriptions such as 
“common” or “rare.” On average, individuals tend to overestimate risk likelihood when provided 
with only these risk labels compared with when they are provided with numeric information 
(Peters, 2014). Research has shown adverse event information presented in a numerical format is 
easier to interpret than adverse event information presented in a non-numerical format (Peters, 
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2014; West, 2013). However, research has not pinpointed which method of conveying this 
numerical information is the most effective (West, 2013; Lipkus, 2007).  
Many forms of WMI such as the ones approved by the FDA are lengthy, poorly 
organized, have small print, and are not easily accessible for certain patient populations such as 
the elderly or those with low literacy levels (Schwartz, 2013). A new form of WMI, the Drugs 
Facts Box, is a one-page summary of benefit and harm data for each indication of a drug. To 
improve accessibility, a series of studies have demonstrated that most consumers understand 
Drug Facts Boxes much more easily and that they improve decision making. Therefore, this 
study will utilize a modified Drug Facts Box modeled after Schwartz and colleagues as the 
method of conveying information to the participants (Schwartz, 2013).  
 Many qualitative studies have demonstrated that for many people considering primary 
prevention interventions, there is a “cost” associated with the very act of taking a medication 
(Benson, 2002). In one particular study by Fried and colleagues, participants recognized adverse 
effects of medications as a competing outcome that influenced their treatment decision-making 
(Fried, 2011). There is also still considerable variability in the amount of benefit that a primary 
prevention therapy would need to provide in order for a patient to be willing to take the 
medication. However, all of these studies leave unanswered the question of the relative 
importance of benefits and harms of medications and how patients weigh these against one 
another when making the decision to initiate a therapy (Benson, 2002). Additionally, studies 
have shown that the objective severity of a patients’ disease conditions, can predict their 
adherence and willingness to take a medication (DiMatteo, 2007). However, further studies are 
required to assess the scope of influence that disease severity has on the decision-making 
process.  
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The objective of this study is to assess how both the severity of illness and the probability 
of side effects influences patient perceptions of medication risk and benefit as well as their 
decision to take the medication. The study hypotheses were as follows: (1) individuals will be 
most willing to take a medication when illness severity is high, and less willing to take a 
medication when illness severity is low, (2) individuals will be most willing to take a medication 
and will consider it safest when the probability of a side-effect is low, and (3) non-quantitative 
side effect information will be interpreted similarly to high side effect probability information.  
Materials and Methods 
 Amazon Mechanical Turk was used to recruit participants for the study. The title of the 
survey link that appeared on Mechanical Turk was “Answer a survey about prescription 
medication information.” The full description of the study was: “We are conducting a research 
study to learn more about how people interpret information about prescription medications. The 
survey takes 5 to 10 minutes to complete.” The survey was administered via Qualtrics® software 
and the study was limited to participants aged 18 and older in the United States. A total of 518 
people accessed the link and started the survey, however, 17 individuals who started the survey 
did not complete it. Additionally, 14 individuals failed an attention check question that appeared 
in the middle of the survey. This question asked participants to select “Fair” as the response. If 
individuals selected any other response, a skip pattern was invoked in which they were prevented 
from completing the rest of the survey. Thus, a total of 487 individuals participated in the study. 
Each participant was paid fifty cents for completing the survey. The survey was completed on 
June 11, 2015. 
Experimental Materials 
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The study utilized a 3 x 2 experimental research design with participants randomized to 
experimental condition in which they read a scenario about a hypothetical medication. Two 
factors were experimentally manipulated: illness severity and probability of medication side 
effects. Illness severity had two levels: mild and serious. Participants assigned to the mild illness 
severity condition read the following scenario: “Imagine you are having occasional insomnia, or 
difficulty sleeping. You have trouble falling asleep for about 30 minutes and/or wake up 1-2 
times in the middle of the night about 2-3 times a month. This results in you sometimes feeling 
tired all the next day. You visit your family doctor and he prescribes you SLEEPX, which will 
help you fall asleep and stay asleep every night. The directions say ‘Take one tablet by mouth 
once daily for sleep.’ He gives you a fact sheet with information about SLEEPX.” For 
individuals assigned to the severe illness severity condition, the first two sentences of the 
scenario read: “Imagine you are having frequent insomnia, or difficulty sleeping. You often have 
trouble falling asleep for about 2 hours and/or wake up 8-10 times in the middle of the night at 
least 2-3 times a week.’ The rest of the scenario was the same as the one used in the mild 
severity condition. Prior to the launch of data collection, we conducted a small study to 
determine if the illness severity descriptions adequately manipulated the variable.1 
Each participant also viewed information about medication side effects (SE) in 1 of 3 
probability conditions (i.e. Non-Quantitative, Low SE Probability, and High SE Probability). The 
information was presented to each participant in the form of a Drug Facts Box. Figure 1 shows 
                                                          
1 A total of 62 individuals completed the manipulation check survey. They were each paid fifty 
cents for completing the survey. Data was collected on June 4, 2015. Participants were presented 
with a Drug Facts Box and were asked “If you had this health problem, how serious would you 
consider it (Rate on a scale from 0-6, with 6 being the most serious.” Two versions of the Drug 
Facts Box were displayed, the Serious Illness Severity-High SE Probability and Mild Illness 
Severity-High SE Probability groups. Results and analysis revealed that the difference in 
perceived illness severity (mild vs. severe) was significant (F= -2.32, p= 0.0236). 
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the scenario and Drugs Facts Box reviewed by participants in the Mild Illness Severity-Low SE 
Probability group. The probability of adverse effects in the High SE Probability condition was 
four times higher than in the Low SE Probability condition. This factor was chosen to maximize 
the difference between the probabilities viewed by participants in the high SE and low SE 
conditions. The Non-Quantitative versions of this information simply listed the side effects and 
did not provide any information about the frequency of the side effects. The side effects listed in 
the Drugs Facts Box were the same for all conditions.  
Measures 
Outcome variables: 
Primary Outcome Variable. The primary outcome variable was willingness to take the 
medication and was assessed by asking, “How likely is it that you would take this medication?” 
Responses were measured on a 7-point scale that ranged from 0=Very Unlikely to 6=Very Likely. 
Next, participants were asked to indicate their most important reason for how likely or unlikely 
they were to take the medication. This measure was adapted from Peters and colleagues (Peters 
et al., 2014). Options provided were: a) most of the adverse events are not very serious; b) any 
serious adverse events are very unlikely; c) prefer to avoid taking medications and will do 
something else; d) there are too many possible adverse events; e) a lot of people will experience 
at least one of the adverse events, and I don’t want to be one of them; f) I would only take it 
occasionally, so I don’t mind; g) I don’t think the condition is serious enough to require this 
medication; and h) none of the above.  
Secondary Outcome Variables. Five secondary outcome variables were assessed. First, 
participants were asked whether they agreed or disagreed with the statement, “The potential 
benefits of taking this medication outweigh the potential risks.” Responses were recorded on a 7-
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point scale that ranged from 0=Strongly disagree to 6=Strongly agree. Second, participants were 
asked “How safe or dangerous is this medication?” Responses were recorded on a 7-point scale 
that ranged from 0= Very dangerous to 6=Very safe. Third, participants were asked “If you had 
insomnia and took this medication, how likely is the medication to help you?” Fourth, 
participants were asked “If you had insomnia and took this medication, how likely is the 
medication to cause side effects?” Finally, respondents were asked “How likely are you to 
recommend this medication to somebody else with insomnia?” The last three questions were all 
answered on 7-point scales that ranged from 0=Very unlikely to 6=Very likely. 
Health and Medication Use 
 Respondents were asked to rate their overall health on a 5-point scale that ranged from 
1=Poor to 5=Excellent. They were also asked whether they were currently taking any 
prescription medications (Yes/No) and whether they had ever experienced a serious medication 
side effect (Yes/No).  
Demographic Characteristics 
 Several socio-demographic characteristics were assessed, including: age (in years), 
gender, race (dichotomized as White/Nonwhite), education (dichotomized as college 
graduate/not college graduate), and status as a healthcare professional (Yes/No). 
Statistical Analysis 
 Analyses were conducted using PC-SAS version 9.4 (SAS Institute Inc., 2007). 
Characteristics of study participants were summarized using descriptive statistics. The effects of 
the two experimental conditions, high versus low illness severity and high versus low versus 
non-qualitative probability information, on the primary and secondary outcome variables were 
assessed using linear regression models. An interaction between the two experimental conditions 
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was included in each regression model. Statistical significance was evaluated with alpha error set 
at 0.05. Also, a dichotomous indicator variable was created for each possible reason listed on the 
survey. The reasons for willingness to take the medication were coded “1” if the target reason 
was selected or “0” if any other reason was selected. A chi-squared test was performed on each 
indicator variable to determine if it varied as a function of the experimental conditions. Socio-
demographic characteristics were also evaluated for potential confounding. Each regression 
model controlled for age, gender, race, education, health status, current medication use, and 
experience of serious medication side-effects. 
Results 
 The mean age of study participants (N=487) was 31.95 (SD=10.1). Participants were 
mostly male (59.8%) and white (76.8%), with approximately half having a college degree 
(49.9%). Participants reported they were in either excellent (12.1%), very good (38.4%), good 
(38.6%), fair (9.9%), or poor (1.0%) health. There were no significant between group differences 
for any socio-demographic characteristics. The percentage of participants who were currently 
using a prescription medication was 42.3% and 19.5% of participants reported having 
experienced a serious medication-related side effect in the past. The interaction between the two 
experimental conditions, severity of disease and probability of side effects, was not statistically 
significant for any of the outcome variables examined. 
Effect of Disease Severity on Outcome Variables 
 In regression analyses, disease severity was a significant predictor of likelihood of taking 
the medication (F=7.80, p= 0.0054), believing that medication benefits outweigh the risks (F= 
12.43, p= 0.0005), believing that the medication is likely to help (F= 4.05, p= 0.0447), and 
likelihood of recommending the medication to others (F= 5.62, p= 0.0181). The first set of 
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columns in Table 1 compares the responses of participants in the mild illness severity group to 
those in the severe illness severity group. Individuals who were in the severe illness severity 
group were more likely to report that: 1) medication benefits outweighed the risks, 2) they would 
be likely to take the medication, 3) the medication was likely to help, and 4) they would 
recommend the medication to others. These results were consistent with the study hypotheses. 
Disease severity did not impact participant responses of how safe or dangerous the medication 
was or how likely the medication was to cause side effects.  
Effect of Medication Side Effect (SE) Probability on Outcome Variables 
 In the regression analyses, medication side effect probability was a significant predictor 
of likelihood of taking the medication (F= 11.09, p< 0.0001), believing that medication benefits 
outweigh the risks (F= 18.56, p= <0.0001), believing that the medication is likely to help (F= 
5.73, p= 0.0035), believing that the medication is safe (F= 7.43, p= 0.0007), believing that the 
medication is likely to cause side effects (F= 73.57, p< 0.0001), and likelihood of recommending 
the medication to others (F= 8.31, p= 0.0003). The second set of columns in Table 1 compares 
the responses of participants who received low, high, or non-quantitative SE information.  
 Consistent with study hypotheses, individuals presented with low SE probability 
information compared to those presented with high SE probability information were more likely 
to report medication benefits outweighed the risks, were more likely to take the medication, 
believed the medication was more likely to help, believed that the medication was safer, believed 
the medication was less likely to cause side effects, and were more likely to recommend the 
medication to others. Responses from the non-quantitative SE probability group were also 
statistically different from the responses for the low SE probability group for all variables. 
However, responses for the non-quantitative SE probability group was statistically different from 
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the high SE probability group for only one outcome variable: how likely the medication is to 
cause side effects.  
Reasons for Willingness to Take the Medication 
 Table 2 displays the number of participants (and corresponding percentages) who 
identified their most important reason for being likely or unlikely to take the medication, 
stratified by illness severity and SE probability information format. The most common reason 
given was “Most of the adverse events are not very serious” followed by “Prefer to avoid taking 
medications and will do something else.” Individuals in the low illness severity group were more 
likely than individuals in the high illness severity group to choose “I don’t think the condition is 
serious enough to require this medication” (x2(1)= 4.91, p= 0.027). Participants in the low SE 
probability information group were more likely than the participants in the high SE probability 
and non-quantitative information groups to indicate “Most of the adverse events are not very 
serious” (x2(1)=12.42, p= 0.002). Participants in the high SE probability information group were 
more likely to indicate “A lot of people will experience at least one of the adverse events, and I 
don’t want to be one of them” (x2(1)=24.73, p<0.0001) as their primary reason. Participants in 
the non-quantitative SE probability information group were more likely to choose the reason “I 
don’t think the condition is serious enough to require this medication” (x2(1)=11.96, p= 0.0025)  
than the high SE probability and non-quantitative information groups.  
Discussion 
The results for the primary predictor variable, illness severity, were consistent with the 
original hypotheses. Participants exposed to the serious illness severity group were more likely to 
take the medication, believed the medication benefits outweighed the risks, believed the 
medication was likely to help, and were more likely to recommend the medication to others. This 
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contradicts the study by DiMatteo and colleagues, which concluded that patients who are most 
severely ill with serious diseases may be at greatest risk for not taking the medication (DiMatteo, 
2007). However, the results demonstrated in this paper indicate that participants may be more 
aware of their condition when it is of serious illness severity and would be more likely to take the 
medication to alleviate their symptoms, as hypothesized. In comparison, participants with lower 
severity illnesses may not consider medications as important or useful and may be less willing to 
take the medication. 
Medication side effect probability was a significant predictor of all outcome variables 
(Table 1). Individuals presented with low SE probability information compared to those 
presented with high SE probability information were more likely to view the medication 
positively and overall, were more likely to take the medication. This is consistent with past 
studies that have shown high risk adverse event profiles being associated with less willingness to 
take the medication. It suggests that patients do not want to experience the unpleasant side 
effects associated with medications and believe the risks outweigh the benefits that a medication 
may provide. A unique observation was seen with the non-quantitative SE probability group. It 
was significantly different for all outcome variables from the low SE probability group, but 
statistically different from the high SE probability group for only one outcome variable: how 
likely the medication is to cause side effects. This suggests that when side effect probabilities are 
not provided to patients, they tend to respond as though the probabilities are high. This is 
consistent with the predicted hypothesis in which we conjectured that non-quantitative SE 
information would be interpreted similarly to high SE probability information. A side effect is 
typically labeled as “common” if it occurs in at 1-10% of people (Peters, 2014). Since the non-
quantitative SE information was relatively indistinguishable from the high SE probability 
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information, participants interpreted side effects with no numeric information at all as “common” 
side effects. This confirms the importance of providing numeric probabilities with side effect 
information (Peters, 2014). We can conclude if only the names of side effects are provided to 
patients, they have a higher likelihood of not taking the medication. 
The most common reasons for being likely or unlikely to take the medication was “Most 
of the adverse events are not very serious” and “Prefer to avoid taking medications and will do 
something else.” The severity of the side effects played a role in whether the participant would 
take the medication. Whether participants interpreted severity as the probability of occurring or 
the adverse event itself (rash, feeling drowsy during daytime, upset stomach, headache) is 
unknown. The fact that individuals in the low illness severity group were more likely than 
individuals in the high illness severity group to choose “I don’t think the condition is serious 
enough to require this medication” further validates and reiterates the general notion derived 
from this study: low illness severity can lead to less willingness to take the medication. 
Participants in the low SE probability group were more likely than those in the high SE or non-
quantitative probability groups to choose “Any serious adverse events are very unlikely.” This 
indicates that they were accurately able to assess on their own accord that adverse events 
presented with numerical probabilities <10% were uncommon. It was also interesting to find that 
participants in the non-quantitative SE probability group were more likely than the other two 
groups to choose the reason “I don’t think the condition is serious enough to require this 
medication.” Additionally, despite the fact that the non-quantitative and high probability 
information groups were equally likely to take the medication (p<0.05), they provided different 
main reasons for why. The non-quantitative probability group provided the reason “I don’t think 
the condition is serious enough to require this medication” while the high SE probability group 
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indicated that “A lot of people will experience at least one of the adverse events, and I don’t 
want to be one of them.” This reasoning may indicate that when the probability of side effects is 
unknown, patients may set a higher bar for how severe their condition needs to be in order for 
them to make the decision to initiate therapy. In other words, the condition may need to be very 
severe in order to offset the unknown risk.  
This study has several limitations which should be noted. First, the hypothetical patients 
used in this study were obtained through a crowdsourcing internet marketplace. Since they were 
not involved in a real-life clinical situation and did not personally have the disease state 
(insomnia) that was presented in the scenario, the extent to which the participant responses 
reflect the decisions they would make in real life is unknown. Additionally, most of the 
participants were healthy, young, and well-educated. This does not accurately represent the 
general population demographic in real life that frequently require multiple medications for 
chronic disease states (poor health, older, and less educated). Lastly, insomnia was the disease 
state chosen for this study, however, the results may not be generalizable to other disease states. 
For example, some patients may consider all stages of cancer to be more severe than the highest 
severity of insomnia and all stages of insomnia to be more severe than the highest severity of 
headaches. Severity of illness may be objectively perceived by patients within the disease state 
itself. Whether the same results would occur in varying severities of other disease states is 
unknown. 
Despite these limitations, our findings suggest that both illness severity and side effect 
probabilities have an impact on patient perceptions of medication risks and their willingness to 
take the medication. It is important for healthcare professionals to emphasize the importance of 
adherence to medications regardless of disease severity due to the risk of progression of the 
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disease state and worsening of clinical outcomes. Providing numerical probability information 
can prevent false notions from developing about medications and can improve informed 
decision-making.  
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Table 1. Means (SE) for Outcome Variables by Illness Severity and Side Effect Probability (N=487) 
 
*p < 0.05  **p < 0.01  ***p < 0.001 ****p < 0.001 
¥ Means with the same letter (‘a’, ‘b’, ‘c’) are not significantly different. 
 
 
 
 
 
 
 
Outcome Variable 
 Illness Severity  Side Effect Probability¥ 
Mild 
(N=261) 
Severe 
(N=226) 
Non-Quantitative 
(N=164) 
Low Probability 
(N=150) 
High Probability 
(N=173) 
Likely to Take 
Medication 
 3.05 
(0.12) 
3.43** 
(0.12) 
 3.09a 
(0.14)  
3.75b 
(0.15) 
2.89a 
(0.13) 
Medication Benefits 
Outweigh Risks 
 3.48 
(0.10) 
3.87**** 
(0.10) 
 3.54a 
(0.12) 
4.22b 
(0.12) 
3.29a 
(0.11) 
Medication Likely to 
Help 
 4.38 
(0.06) 
4.54* 
(0.07) 
 4.36a 
(0.07) 
4.67b 
(0.08) 
4.34a 
(0.09) 
Medication Safe  3.72 
(0.07) 
3.94 
(0.07) 
 3.81a 
(0.09) 
4.22b 
(0.09) 
3.79a 
(0.08) 
Medication Likely to 
Cause Side Effects 
 3.15 
(0.09) 
3.34 
(0.10) 
 3.49a 
(0.09) 
2.22b 
(0.11) 
3.87c 
(0.09) 
Likely to 
Recommend 
Medication to Others 
 2.99 
(0.10) 
3.26* 
(0.10) 
 3.05a 
(0.11) 
3.49b 
(0.12) 
2.85a 
(0.12) 
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Table 2. Most Important Reason (%) for Being Likely or Unlikely to Take Medication (N=487) 
 
    Outcome Variable 
                Illness Severity                                                              Side Effect Probability¥ 
Mild 
(N=261) 
Severe 
(N=226) 
 Non-Quantitative 
(N=164) 
Low Probability 
(N=150) 
High Probability 
(N=173) 
Most of the side 
effects not serious 
 71 
(27.59) 
67 
(29.65) 
 38a 
(23.17) 
59b 
(39.33) 
42a 
(24.28) 
The serious side 
effects not likely 
 19 
(7.28) 
25 
(11.06) 
 13 
(7.93) 
20 
(13.33) 
11 
(6.36) 
Prefer to avoid 
medications 
 47 
(18.01) 
35 
(15.49) 
 26 
(15.85) 
29 
(19.33) 
27 
(15.61) 
Too many possible 
side effects 
 28 
(10.73) 
25 
(11.06) 
 20 
(12.20) 
10 
(6.67) 
23 
(13.29) 
Don’t want to be the 
one who has a side 
effect 
 26 
(9.96) 
25 
(11.06) 
 11a 
(6.71) 
6b 
(4.00) 
34c 
(19.65) 
Only have to take 
occasionally, so don’t 
mind 
 31 
(11.88) 
26 
(11.50) 
 22 
(13.41) 
16 
(10.67) 
19 
(10.98) 
   
3.05 
 
 
3.49 
 
 
2.85**** 
 
Condition not serious 
enough 
 36 
(13.79) 
17* 
(7.52) 
 29a 
(17.68) 
10b 
(6.67) 
14c 
(8.09) 
     
None of the above  2 
(0.77) 
6 
(2.65) 
 5 
(3.05) 
0 
(0.00) 
3 
(1.73) 
     
*p < 0.05   
¥ Means with the same letter (‘a’, ‘b’, ‘c’) are not significantly different. 
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Figure 1. Example prompt and Drug Facts Box 
 
 
